Phase 2 clinical trial of CCX168, an orally administered C5aR antagonist, in patients with ANCA-associated renal vasculitis (CLEAR)
(2013) American Society of Nephrology — Location: Atlanta, USA (5.November.2013)
Files
BruchfeldetalPhase2clinicaltrialofCCX168abstract2013.pdf
Restricted Access - Adobe PDF
- 82.29 KB
Details
- Authors
- Affiliations
Citations
Bruchfeld, A., Schaier, M., Harper, L., Jadoul, M., Segelmark, M., Szombati, I., Venning, M., Hamilton, P., Hugo, C., Van Daele, P. L. A., Viklicky, O., Jayne, D. R. W., Potarca, A., Jaen, J. C., Schall, T. J., & Bekker, P. (2013). Phase 2 clinical trial of CCX168, an orally administered C5aR antagonist, in patients with ANCA-associated renal vasculitis (CLEAR). American Society of Nephrology, Atlanta, USA. https://hdl.handle.net/2078.5/199721